Outrage as new Zygotron logo leaked

Sunday or not, our legal team are hurtling into action as the new logo for Zygotron, carefully designed to show our forward thinking and development-orientedness.

Notably, its area increases 4-fold, when its dimension increases only 2-fold.

This is a major breakthrough by our technical director, Prof Archi Medes, and we are confident that this will deliver a turnaround for the effect size of our next trial.

Do not under any circumstances view the new logo at https://twitter.com/ProfDFrancis/status/934817479993581570

Int J Cardiol counsel anxious

Int J Cardiol general counsel anxious

“When a distinguished but elderly scientist states that something is possible, he is almost certainly right.

When he states that something is impossible, he is very probably wrong.”

Arthur C Clarke’s First Law

Jealous rivals of the Zygotron Metadynamics IP portfolio attempted to disrupt the smooth progress of our scientific and financial transactions. Our legal team delivered appropriate bulletins to ensure that no news media or scientific journal would carry the story. Only one journal declined to see reason, and we can resume our focus on the low hanging fruit of the desperately unmet need for portfolio investors for IP-protected therapy for heart disease.

Refutation of claims of discrepancies

The claims of Appendix 1 are convincingly refuted in this CME-accredited webcast (click the Webcast link for 381).

A finding of this level of revolutionary importance should indeed be presented as many times as is required in as many fora as are desired.

CEO Broker Call

I was delighted to be able to reach out to all of you earlier today to reveal to you the paradigm shift that we have achieved through Zygotron‘s innovative out-of-the-box thinking modalities.

CEO ZygotronThe outstandingly positive results of our pivotal trial speak to our glowing destiny. I trust your discretion. Although the headline values may be reported, we must keep the details confidential for now, until rubber-stamped by the journal with which we have formed an arrangement, or at least until recruitment is complete.

To better position the company to compete in a fragmented and competitive market, Zygotron will transition from the launch thoughtspace that spanned the full panorama of cellular biotherapeutics, to the more focused business environment of cardiac dysfunction in heart failure and myocardial infarction. Manufacturing of our key blastosome nucelobionics technology will fluidly move to the new phytometabolic platform during the next FY, with key deliverables being hit at end of play.

We are committed to working towards right-sized standards of scientific and business ethics, and in alignment with this we have continued our ongoing transformation program.

Congress Themed session - The Emerging Role of Metadynamics

Congress Session “The Emerging Role of Metadynamics” – arranged by our consultants

We have secured the major thought leaders in heart failure in all 3 continents through our program of re-purposing of scientific congresses with global reach, and they have confirmed their brand alignment to Zygotron which is already reaping dividends. We have gone offline and widened our footprint arising through funding issues in Continuing Medical Education systems to transition vanilla education programs into consciousness-raising themed sessions that are market-generative.

Through our influential contacts we have obtained a highly competitive place in the family of sessions entitled “The Emerging Role Of …” which focus on therapies whose validity is obvious to the far-sighted visionaries of the financial world long before it becomes apparent through conventional pre-paradigm-shift research processes.

Our legal department has hit the ground running with all hands on deck, interfacing with the major cardiovascular journals to underline their fiduciary responsibility to Zygotron as paying customers, and the mutually undesirable consequences of any remarks that are not win-win.

We have bandwidthed the resonance of our internal knowledge economy, keeping our scientific knowhow segregated into silos so that no individual human capital element could externalize our technology to a competitor. While this introduces some challenges our Chief Medical Officer makes face-time to touch base with our statistical and marketing leads to ensure the idea flow is not vulnerable to flight risk.

We are in a stronger position today than ever before.

Charles Dawson BA, MBA
CEO Zygotron Metadynamics

Allegations unfounded – investor relief

Investors may have been concerned by press speculation over an article claiming there are a few errors in the foundational work of the pioneer in bone marrow stem cells.

Int J Cardiol Zygotron case

Zygotron / Int J Cardiol libel case near resolution

Fundamentals as secure as ever

Investors should should take full reassurance that we at Zygotron Metadynamics have conducted industry-standard due diligence on the foundations of our method. There are dozens of landmark works which have been carefully checked by leading scientific bodies time and time again, and found to be valid. The senior staff of these prestigious journals have personally re-examined the research data and verified that the science is sound, which the authors of the critical article have now been forced by our legal team to accept:

We have full confidence in the science that underpins our highly efficient technology pipleine.

Recently in Nature (a scientific journal) the pioneering thought-leader has entirely refuted all the claims of arithmetical, factual and biological impossibilities. As a company we expect the irresponsible baseless allegations to be forced to be retracted in due course due to the fine self-correcting nature of science. These discussions are best held openly rather than in the closed world of scientific journals because of the greater opportunities for blue-sky thinking and less distraction by unimportant arithmetical minutiae.

International Study of Cardiogeneration by Autologous Marrow Utilization

Our pivotal clinical trial IS/C-AMU, that screened over 1000 patients, will next week randomize its 23rd and final patient. The steering committee has recommended, having reviewed the radionucleide ejection fraction data, that this variable is not the ideal primary endpoint. Patients will shortly be unblinded to their study arm prior to final evaluation of the NYHA score that is the new primary endpoint, and then modern radiation-free echocardiographic evaluation of ejection fraction will be carried out.

The journal has given us permission to change the primary endpoint due to extreme interest of this study to its readers, its unique nature and the strong likelihood of augmentation of the journal’s Impact Factor as a result.

Debbie Moulay CSO

Debbie Moulay drilled down on the statistical results

The final result is a paradigm shift in therapeutic efficacy: “NYHA class falls to 1.5 (SD 0.2) in the 19 patients in the active arm while it did not change signficantly (NYHA 3.4, SD 0.1) in the 8 patients in the control arm”, according to Debbie Moulay our chief statistician. “This is of the utmost significance, statistically, clinically and financially.”

By popular demand, patients are now allowed to change between randomized arms if clinically appropriate in light of their symptomatic and clinical evaluation. We have also been granted permission to include non-randomized patients inside our randomized trial. This innovative process is not yet permitted in less forward-thinking fields but we have successfully argued that the unique groundbreaking status of our field makes us a special case. Colleagues have successfully achieved this in a journal called The Lancet and have thereby set for us an unimpeachable precedent. Incidentally, our therapy is even more effective than theirs.

Accepted for publication contingent on strongly positive results

The leading cardiac journal that looks especially favourably on stem cell research has agreed to pre-accept our study for publication based on the expected positive results. We are delighted with this partnership which provides the journal with consistent positive results and high citations, and our corporation with a distribution network of high-quality typeset PDF reports straight onto iPads of thousands of cardiologists across the world.

Going forward
We look forward to updating our investors on the next webcast on the superb progress achieved by our clinical trial team and our plans for sale to a major global medical therapeutics corporation.

Dusseldorf data discrepancy deftly deflected

Network HQ

Our legal affairs department, numbering 173, is the largest division of the corporation, forming 46% of our total headcount of 510.

A successful educational program by our legal team who moved quickly to resolve the impending situation has ensured that no reference to Zygotron itself remains in the accusations of errors that are shortly to come to light.

There is an undercurrent of competition in the bone marrow stem cell world that occasionally surfaces with persons without scientific pedigree attempting to disrupt our business as usual. While we firmly support freedom of speech, we believe such liberty should be exercised at the proper time and place, i.e. in court, rather than in journals.

We are unafraid of the Streisand effect, and have no hesitation in listing the items here, confident that we are free from implication therein. The trusty sword of scientific justice will comprehensively reject the criticisms in due course.

SFI – Düsseldorf Discrepancies – Int J Cardiol 2013 UNFOUNDED ALLEGATIONS

SFI – Online Appendix 1 DoH Test – STAR

SFI – Online Appendix 2 IACT-Regeneration versus AHA 2006 poster

SFI – Online Appendix 3 Star Citations with discrepancies

SFI – Online Appendix 4 IACT Citations with discrepancies

SFI – Online Appendix 5 DoH Advanced Test – BALANCE

SFI – Online Appendix 6 Journal STAR

SFI – Online Appendix 7 Journal 10 years

SFI – Online Appendix 8 Journal IACT

SFI – Online Appendix 9 Journal BALANCE

The Zygotron Heritage

Emilio Zyg

Zyg at work, in his editorium

Unlike many other companies recently hastily assembled to ride the wave of investor enthusiasm for the unknown, Zygotron Metadynamics traces its origins to the true innovator of bone marrow stem cell therapy.

Our founder was a highly talented polymath whose gifts spanned the breadth of human achievement from biology to sociology to mathematics.

Qualifying in Warsaw and training in Vienna, Paris and Milan, Prof Dr Emilio Zyg painstakingly developed, through a peripatetic lifestyle across top centers in Europe, his storehouse of knowledge on which our company is based. In 1952 time he married Magdalena, scion of the secretive Lamprecht-Baumgartner dynasty which through a network of private shareholdings controlled several heavy industries in central Europe. This endowed him with a substantial fortune which he committed to invest in the furtherance of realizing his ideas.

Zygotron HQ

Early color photograph of Zygotron HQ, 1959

He established a center of excellence for bone marrow stem cell researchers worldwide which brought many liberated thinkers together in a spirit of brotherhood and innovation. The important work they initiated there has had ramifications of unparalleled importance for the development of the field since then. A modest man, he sought no publicity and never gave interviews, preferring to spend his time quietly analyzing and editing the institute’s scientific data, and setting strategic direction. He knew the many staff by name individually although, being shy, he rarely engaged in conversation other than brief discourse into his novel ideas on hyperbolic non-linear calculus that have become a foundation for our field, both within our company and beyond.

To this day workers outside the company have difficulty following our advanced calculations. This is the burden of being the intellectual descendants of a genius.

As the institute grew, the headquarters building – grand though it was – became constraining and was replaced by numerous smaller institutes around the globe, principally in Europe and especially in Germany. The largest and most popular among stem cell pioneers was the spacious accommodation near Düsseldorf, where he found the company most convivial and the climate most pleasing.

Dusseldorf Pioneers 1961

Happier times – Düsseldorf senior leadership, pre-schism 1961

Sadly, as is common in the highly charged atmosphere of world leading scientists, a split in the group developed, and a faction broke away from the Zyg mainstream in the mid 1960’s. Although sharing research methodology, and indeed some rather complex domestic arrangements, Zyg’s main group adhered to original aspiration of developing a solid science with commercial aspirations, while the breakaway group struck out boldly for immediate clinical application, with less attention to detail. The splinter group, able to obtain funding through delivering hopeful therapy, flourished more prominently in the media and is now world-renowned.

Zyg never discussed the split, preferring to puff on his pipe and raise an eyebrow sadly. “He was like a brother to me, not so long ago,” is all he would lament of his erstwhile deputy. The groups gradually stopped intermixing socially and Zyg spent more time supervising the construction of his retirement villa, Hotel Paracrine.

His death in 1981 has not dimmed the light he shone into this world. His family have maintained the company at the forefront of science through generous funding and infusion of fresh talent drawn from the top echelons of the international business world. Each day at our headquarters staff file past a portrait of this great man of science who is our inspiration.

We are still today dedicated to bringing his imagination into reality.